Anthony Recupero Sells 21,049 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) insider Anthony Recupero sold 21,049 shares of the business’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $15.40, for a total transaction of $324,154.60. Following the completion of the sale, the insider directly owned 243,418 shares of the company’s stock, valued at approximately $3,748,637.20. This trade represents a 7.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

SiBone Stock Performance

Shares of SiBone stock opened at $15.47 on Friday. The stock has a market capitalization of $671.24 million, a price-to-earnings ratio of -30.33 and a beta of 0.69. The firm’s fifty day simple moving average is $17.90 and its 200-day simple moving average is $16.85. The company has a debt-to-equity ratio of 0.21, a current ratio of 7.97 and a quick ratio of 6.62. SiBone has a 12 month low of $12.49 and a 12 month high of $21.89.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on SIBN shares. TD Cowen raised SiBone to a “strong-buy” rating in a report on Tuesday, January 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of SiBone in a report on Monday, December 29th. Morgan Stanley upped their price target on shares of SiBone from $20.00 to $23.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Needham & Company LLC raised their price objective on shares of SiBone from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Finally, Truist Financial boosted their price objective on shares of SiBone from $21.00 to $23.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, SiBone has an average rating of “Moderate Buy” and a consensus price target of $24.33.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in SiBone by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after buying an additional 1,053 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of SiBone during the 1st quarter worth about $225,000. Goldman Sachs Group Inc. boosted its position in shares of SiBone by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock worth $5,328,000 after acquiring an additional 83,919 shares during the last quarter. Jane Street Group LLC purchased a new stake in SiBone in the first quarter valued at approximately $1,818,000. Finally, Y Intercept Hong Kong Ltd increased its position in SiBone by 65.1% during the second quarter. Y Intercept Hong Kong Ltd now owns 19,047 shares of the company’s stock worth $358,000 after purchasing an additional 7,512 shares during the last quarter. 98.11% of the stock is currently owned by institutional investors and hedge funds.

About SiBone

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.